Day: October 30, 2026

OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer

Final positive readout for primary and several secondary endpoints presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at...

FEM By UPSA Highlights Growing Body of Research on Non-Hormonal Menopause Support, Including Studies in Breast Cancer Survivors

Decades of research address key considerations for healthcare professionals discussing non-hormonal menopause options with patientsRUEIL-MALMAISON, France, Oct. 29, 2026 (GLOBE...

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session...

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...

error: Content is protected !!